Cargando…
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumor-specific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245068/ https://www.ncbi.nlm.nih.gov/pubmed/18794792 http://dx.doi.org/10.3390/molecules13081897 |
_version_ | 1783372169703587840 |
---|---|
author | Koukourakis, Georgios V. Kouloulias, Vassilios Koukourakis, Michael J. Zacharias, Georgios A. Zabatis, Haralabos Kouvaris, John |
author_facet | Koukourakis, Georgios V. Kouloulias, Vassilios Koukourakis, Michael J. Zacharias, Georgios A. Zabatis, Haralabos Kouvaris, John |
author_sort | Koukourakis, Georgios V. |
collection | PubMed |
description | Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumor-specific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas. |
format | Online Article Text |
id | pubmed-6245068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62450682018-11-26 Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review Koukourakis, Georgios V. Kouloulias, Vassilios Koukourakis, Michael J. Zacharias, Georgios A. Zabatis, Haralabos Kouvaris, John Molecules Review Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumor-specific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas. MDPI 2008-08-27 /pmc/articles/PMC6245068/ /pubmed/18794792 http://dx.doi.org/10.3390/molecules13081897 Text en © 2008 by the authors. Licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Koukourakis, Georgios V. Kouloulias, Vassilios Koukourakis, Michael J. Zacharias, Georgios A. Zabatis, Haralabos Kouvaris, John Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title_full | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title_fullStr | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title_full_unstemmed | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title_short | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review |
title_sort | efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245068/ https://www.ncbi.nlm.nih.gov/pubmed/18794792 http://dx.doi.org/10.3390/molecules13081897 |
work_keys_str_mv | AT koukourakisgeorgiosv efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview AT koulouliasvassilios efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview AT koukourakismichaelj efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview AT zachariasgeorgiosa efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview AT zabatisharalabos efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview AT kouvarisjohn efficacyoftheoralfluorouracilprodrugcapecitabineincancertreatmentareview |